TLDR Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
In a study from June 1, 2018, researchers assessed the effectiveness of 2% topical tofacitinib in 11 pediatric patients, aged 4 to 16, with alopecia areata, alopecia totalis, and alopecia universalis who had not responded to previous treatments. After using the topical tofacitinib for an average of 34.5 weeks, patients experienced an average 32.3% decrease in Severity of Alopecia Tool (SALT) scores, with 8 showing improvement and 3 achieving cosmetically acceptable hair regrowth. The treatment was generally well-tolerated, with only one instance of application-site irritation and no serious side effects reported. The study suggested that topical tofacitinib could be a viable second-line treatment for these conditions, but highlighted the need for larger, controlled studies to confirm its efficacy and identify predictors of a positive response.
48 citations,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
77 citations,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
83 citations,
June 2017 in “Journal of the American Academy of Dermatology” Topical JAK inhibitors may help children with alopecia areata regrow hair.
78 citations,
April 1984 in “Archives of Dermatology” Minoxidil can help regrow hair in alopecia areata patients.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
77 citations,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
124 citations,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
63 citations,
April 2018 in “Journal of the American Academy of Dermatology” Topical JAK inhibitors may help treat some skin conditions but need more research.
40 citations,
December 2016 in “Journal of Dermatological Treatment” JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
28 citations,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
